STAGE III RECTAL CANCER AJCC V8
Clinical trials for STAGE III RECTAL CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III RECTAL CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III RECTAL CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope: personalized therapy for HIV patients with anal cancer
Disease control OngoingThis study tests a personalized approach for people with HIV and anal cancer. For low-risk patients, standard chemotherapy and radiation are used. For high-risk patients, the immunotherapy drug nivolumab is added after standard treatment to help prevent the cancer from coming bac…
Matched conditions: STAGE III RECTAL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 06:49 UTC
-
New drug combo shows promise in shrinking rectal tumors before surgery
Disease control OngoingThis early-stage study tests the safety of combining the chemotherapy drug TAS-102 with radiation therapy for people with stage II or III rectal cancer that hasn't been treated yet. The goal is to find the safest dose of TAS-102 to use with radiation before surgery. About 19 adul…
Matched conditions: STAGE III RECTAL CANCER AJCC V8
Phase: PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated May 26, 2026 06:46 UTC
-
Triple-Drug chemo may help rectal cancer patients skip surgery
Disease control OngoingThis study compares a three-drug chemotherapy combination (FOLFIRINOX) against standard two-drug combinations (FOLFOX or CAPOX) after radiation in people with stage II or III rectal cancer. The goal is to see if the stronger regimen leads to a complete disappearance of the tumor,…
Matched conditions: STAGE III RECTAL CANCER AJCC V8
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 26, 2026 06:38 UTC
-
New drug cocktail aims to shrink Hard-to-Treat colorectal tumors
Disease control OngoingThis study tests whether adding two targeted drugs (LY3214996 and abemaciclib) to the standard drug cetuximab can shrink tumors in people with advanced colorectal cancer that no longer responds to standard treatment. About 46 adults with metastatic or inoperable colorectal cancer…
Matched conditions: STAGE III RECTAL CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
Could adding an immunotherapy drug shrink tough colorectal tumors?
Disease control OngoingThis study is for people with a specific type of advanced colorectal cancer that has a BRAF gene mutation and is stable (not the MSI-high type). It compares the usual two-drug treatment (encorafenib and cetuximab) against the same two drugs plus an immunotherapy drug called nivol…
Matched conditions: STAGE III RECTAL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Immunotherapy-Radiation combo shows promise against rectal cancer
Disease control OngoingThis study tests whether giving two immunotherapy drugs (nivolumab and ipilimumab) along with a short course of radiation can shrink advanced rectal tumors before surgery. About 31 adults with stage II or III rectal cancer that has a specific genetic feature (MSI-H/dMMR) will rec…
Matched conditions: STAGE III RECTAL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:03 UTC